On January 22, the National Health Commission and the State Administration of Traditional Chinese Medicine jointly issued the “Influenza Diagnosis and Treatment Plan (2025 Edition)” (hereinafter referred to as the “New Edition”). Compared with the “Influenza Diagnosis and Treatment Plan (2020 Edition)” (hereinafter referred to as the “2020 Edition”), the new version includes two anti-influenza virus drugs, Mabaloxavir and Favipiravir. Amantadine and rimantadine were eliminated due to drug resistance issues. At the same time, the new version of the plan clearly stated that it is not recommended to use antiviral drugs with the same mechanism of action in combination. Many pharmacists pointed out to the 21st Century Business Herald reporter that this move is aimed at optimizing the treatment effect and reducing unnecessary side effects. After the replacement of drugs, more and more companies have seen the development potential of the anti-influenza drug market. Competition in the oseltamivir market has ...
On the evening of January 22, Kangtai Biological released its 2024 performance forecast. The performance forecast shows that in 2024, Kangtai Biological will achieve a net profit of 190 million to 270 million yuan, a year-on-year decrease of 77.94% to 68.65%. Last year, this figure was 861 million yuan. Kangtai Biological said that due to market competition, inventory reduction and other factors, the company’s operating income has declined to a certain extent compared with the same period last year; coupled with the increase in fixed asset depreciation expenses, asset impairment, and the termination of the 2023 equity incentive plan to accelerate the exercise of rights, the net profit in 2024 has decreased compared with the same period last year. On January 23, Jiemian News called Kangtai Biological’s secretary’s office. The staff responded that Kangtai Biological’s full range of products has not been reduced in price. Since the unit price of ...
On January 21, the Phase I clinical research launch meeting of the MVA strain monkeypox live attenuated vaccine independently developed by Sinopharm Group China National Biotec Group Shanghai Institute of Biological Products was held at the Henan Provincial Infectious Disease Hospital (Zhengzhou Sixth People’s Hospital). The launch meeting was fully trained and discussed around the clinical trial plan, key points and difficulties of clinical site operations. On September 9, 2024, this monkeypox vaccine obtained the clinical trial notification issued by the State Food and Drug Administration. It is the first monkeypox vaccine approved for clinical trials in my country and is expected to play an important role in the prevention and control of diseases caused by monkeypox virus in my country. On January 22, the first batch of subjects in the Phase I clinical trial of the MVA strain monkeypox live attenuated vaccine were enrolled, marking that my country’s first ...
On January 21, Notai Biotech announced that the dry mixed suspension production line and granule production line in its Zhonghua Pharmaceutical Port factory (Workshop 203) recently received the “Drug GMP Compliance Inspection Notification” (Su Yao Jian Yao Sheng Gao [2025] 037 and [2025] 038) issued by the Jiangsu Provincial Drug Administration, passing the drug GMP compliance inspection. The workshop is designed according to FDA/EMA standards and has introduced first-tier international brand equipment, including Glatt’s wet granulation line, KILIAN’s double-outlet tablet press, SYNTEGON’s capsule filling machine, Glatt’s coating machine, and CAM’s automated packaging line. The designed annual production capacities are 4.5 billion tablets & hard capsules, 36 million bottles of oral dry mixed suspensions & granules, and 450 million bags of granules/powders. The workshop has passed completion acceptance. Notai Biotech stated that the successful GMP compliance inspection of the dry mixed suspension and granule production lines indicates that the production lines ...
Hebei Province has launched the four types of peripheral vascular interventional medical consumables alliance centralized procurement rules four quotation work, and the quotation has been completed recently. 4 types of interventional consumables, recently completed quotation On January 16th, the Hebei Provincial Medical Drug and Equipment Centralized Procurement Center issued a notice on the implementation of the four pricing rules for the centralized and quantity based procurement of four types of medical consumables, including peripheral vascular intervention guidance pathways, in the inter provincial alliance. The notice also includes a list of companies that provide pricing for rule four, and requires them to complete the pricing for rule four. (Read the original text to obtain the list and original file) According to the previously released procurement documents, Rule Four is as follows: (1) After executing the selected rule three, enable the selected rule four, and the selected enterprise in rule four will ...
At the beginning of 2025, news of Shinva Medical once again came of selling hospitals. According to the “Shandong Finance Headlines” report, Shandong Shinva Medical Equipment Co., Ltd. (referred to as “Shinva Medical”, 600587. SH) has officially listed and transferred 55% equity of its subsidiary, Shandong Xinhua Changguo Hospital Investment Management Co., Ltd. (referred to as “Xinhua Changguo” or “the target company”), for a transfer price of 113 million yuan. 01. Stripping off private hospitals for second-class epilepsy Xinhua Changguo, which was officially listed and transferred by Shinva Medical, was established in 2012 with a registered capital of 120 million yuan. It mainly engages in investments in the pharmaceutical and medical service industries. Its wholly-owned subsidiary, Zibo Changguo Hospital (referred to as “Changguo Hospital”), is a privately-owned hospital specializing in epilepsy diagnosis, treatment, and traditional Chinese medicine preparations for epilepsy. When the hospital opened, the media reported that Changguo Hospital ...
NO.1 WHO responds to Trump’s announcement of ‘withdrawal’: hopes the United States will reconsider On January 21st, according to CCTV News, US President Trump signed an executive order announcing the US withdrawal from the World Health Organization. The World Health Organization expressed regret over President Trump’s announcement on his first day in office that the United States would withdraw from the organization. The WHO said that WHO plays a vital role in protecting the health and safety of people around the world, including Americans. The World Health Organization hopes that the United States will reconsider and engage in constructive dialogue with the new US government to maintain the partnership between the United States and the World Health Organization, benefiting the health and well-being of millions of people worldwide. Commentary: The news of the United States’ decision to withdraw from the World Health Organization has attracted widespread attention and concern worldwide, ...
On January 20th Eastern Time, President elect Trump will hold his inauguration ceremony, and the highlight of the ceremony – Trump’s swearing in ceremony and inauguration speech – will take place at 12 noon Eastern Time (i.e. 1 am Beijing Time on January 21st), at which time Trump will officially begin his second presidential term. According to media reports, during a two-hour meeting with Senate Republicans, Trump stated that he has prepared about 100 executive orders and plans to sign them on his first day of office on January 20, 2025. These administrative orders may involve multiple sensitive areas such as tariffs and borders, and will set the tone for the global financial market. Since Trump nominated “vaccine skeptic” Robert Kennedy Jr. as the next Secretary of Health and Human Services last month, the US pharmaceutical industry has been shrouded in gloom. In September of this year, Kennedy Jr. published ...
With the end of 2024, A-shares have also entered the stage of announcing full-year performance. According to statistics from E-Pharmaceutical Manager, as of January 20, in the biopharmaceutical industry, a total of 101 A-share listed companies and 7 Hong Kong-listed companies disclosed performance forecasts. The drama of the strong getting stronger is still being staged in each sub-sector. The Chinese medicine sector, such as Dong-E-E-Jiao, is not only expected to win a net profit of 1.5 billion to 1.6 billion yuan, but also an increase of 30% to 39%; the net profit of the Science and Technology Innovation Board listed company Sansheng Guojian is expected to be 700 million to 712 million yuan, an increase of 137.73% to 162%. In addition, Sinopharm Modern, a chemical pharmaceutical company, Tebao Bio, a biological product company, Synthetic Biology leader Chuan Ning Bio, and orthopedic consumables leader Dabao Medical have also achieved a “double ...
On January 20, 2025, WALVAX, a leading vaccine company in the A-share market, issued an announcement that its operating income is expected to be about 2.86 billion yuan, a sharp drop from 4.114 billion yuan in the same period last year; it is expected that the net profit attributable to parent company in 2024 will be 140 million to 180 million yuan, a decrease of 57% to 67% from 419 million yuan in the same period last year. Net profit after deducting non-recurring gains and losses is expected to be 110 million to 150 million yuan, a decrease of 74% to 81% from 574 million yuan in the same period last year. WALVAX disclosed that the main reasons for the performance changes include: the decline in sales revenue due to the decline in the number of newborns in China and the intensification of market competition. At the same time, in ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.